Disclosed is the use of an antiplatelet thrombolysin in the preparation of a medicine for treating thrombotic thrombocytopenic purpura (TTP). The main pathogenesis of TTP is a von Willebrand factor-cleaving protease, namely, a congenital defect in ADAMTS13 expression or inhibition of ADAMTS13 expression by an autoantibody, thereby resulting in the aggregation of a large number of von Willebrand factors (vWFs) in vivoand forming a plurality of supramaximal multimers mediating the pathological platelet aggregation and forming thrombus, and eventually leading to TTP. The antiplatelet thrombolysin limits the platelet adhesion and aggregation, restores the levels of platelets, erythrocytes and haemoglobin, and at the same time, reduces the level of lactate dehydrogenase, and effectively inhibits thrombocytopenia and schistocytosis hemolytic anemia, and thereby achieves the goal of treating TTP.
